Geneva Advisors’s Medicines Co MDCO Stock Holding History

Geneva Advisors’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-7,485	Closed	-$238K	–	759
2016 Q1	$238K	Buy	+7,485	New	+$244K	﹤0.01%	582

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geneva Advisors's MDCO Position: Q2 2016 in Review

Geneva Advisors sold out of Medicines Co (MDCO) in Q2 2016, closing a stake of 7,485 shares — an estimated $238K sold.

Geneva Advisors first reported a position in MDCO in Q1 2016 and held it in 1 quarter. The position peaked at $238K in Q1 2016. 190 funds tracked by Wall St. Rank hold MDCO as of Q2 2016.

Geneva Advisors reported no remaining Medicines Co position as of Q2 2016 after selling out during the quarter.
Geneva Advisors sold 7,485 Medicines Co shares in Q2 2016, an estimated $238K.
Geneva Advisors first reported a position in Medicines Co in Q1 2016 and held it in 1 quarter.
Geneva Advisors's Medicines Co position peaked at $238K in Q1 2016.
190 funds tracked by Wall St. Rank held Medicines Co as of Q2 2016.

Based on Geneva Advisors's 13F filing for Q2 2016, filed 8 Aug 2016.